Walgreens Boots Alliance Slashes FY23 Adj. EPS Outlook; Stock Down 7% - Update

RTTNews | Pred 509 dňami
Stocktwits
Walgreens Boots Alliance Slashes FY23 Adj. EPS Outlook; Stock Down 7% - Update

(RTTNews) - While reporting financial results for the third quarter on Tuesday, Walgreens Boots Alliance, Inc. (WBA) slashed its adjusted earnings guidance for the full-year 2023 to a range of $4.00 to $4.05 per share from the prior forecast range of $4.45 to $4.65 per share, reflecting challenging consumer and macroeconomic conditions, and lower COVID-19 vaccine and testing volumes.

On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $4.46 per share for the year. Analysts' estimates typically exclude special items.

The company said the fourth quarter is expected to be negatively impacted by a higher effective tax rate, shifting U.S. consumer spending with heightened macro pressures, and the impact of a weaker respiratory season for both U.S. Retail Pharmacy and U.S. Healthcare.

For the fiscal year 2024, Walgreens Boots Alliance is providing preliminary expectations for low- to mid-single digit adjusted operating income growth, with the U.S. Healthcare and U.S. Retail Pharmacy performance more than offsetting headwinds from lower sale and leaseback program benefits, lower COVID-19 contribution, and the sale of holdings in AmerisourceBergen.

The company also raised its Transformational Cost Management Program target to $4.1 billion from $3.5 billion in cumulative savings by fiscal 2024. It is also expecting cost savings of $800 million in fiscal 2024.

The Company said its capital allocation continues to focus on core investments, debt paydown, and dividend payments.

Značky: WBA
Stocktwits
read more
Walgreens To Close 1,200 US Stores

Walgreens To Close 1,200 US Stores

Walgreens announced its plan to close around 1,200 U.S stores over the next three years, including around 500 closures in fiscal 2025, as the drug store chain is facing a challenging U.S. retail environment amid increasing competition. The move, which was announced while reporting a significantly wider net loss in its fourth quarter, is expected to be immediately accretive to adjusted earnings...
RTTNews | Pred 32 dňami
Walgreens, CVS To Sell Abortion Pill Mifepristone Starting In March

Walgreens, CVS To Sell Abortion Pill Mifepristone Starting In March

Pharmacy majors Walgreens Boot Alliance Inc. and CVS Health Corp. will start selling abortion pill mifepristone this month at stores in several states where it is legal. Both companies have received certification from the U.S. Food and Drug Administration to dispense the pill at their retail pharmacies.
RTTNews | Pred 258 dňami
FDA Warns CVS Health, Walgreens Against Unapproved Eye Products

FDA Warns CVS Health, Walgreens Against Unapproved Eye Products

The U.S. Food and Drug Administration has warned eight companies including CVS Health and Walgreens Boots Alliance, Inc. against manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. The agency has issued warning letters to these companies as part of its ongoing effort to protect Americans from potentially harmful ophthalmic products.
RTTNews | Pred 431 dňami
Walgreens, Pearl Health Partner To Boost Value-Based Care Delivery

Walgreens, Pearl Health Partner To Boost Value-Based Care Delivery

Walgreens, a division of Walgreens Boots Alliance, Inc. (WBA), has inked a partnership with Pearl Health to boost and expand value-based care to patients in Medicare in partnership with community-based primary care physicians. The partnership with Pearl Health will enable Walgreens to transition quickly and effectively to value-based care and improve outcomes in the communities they serve.
RTTNews | Pred 432 dňami
Walgreens, CVS Reportedly Plan To Offer Abortion Pills

Walgreens, CVS Reportedly Plan To Offer Abortion Pills

Pharmacy majors Walgreens Boot Alliance Inc. and CVS Health Corp. are planning to offer abortion pills after the U.S. Food and Drug Administration decided to allow retail pharmacies to sell the product in the United States, reports said. On Tuesday, the agency announced a regulatory change allowing mifepristone, which is used in first-trimester abortions, to be dispensed by retail pharmacies.
RTTNews | Pred 682 dňami
Nástroje
Ekonomický kalendár
Market Hours
Interest Rates
Holidays Calendar
Forexový trh
Forex Volatilita
Korelácia Forexu
Novinky na Forexe
forex analysis
COT Údaje
Likvidita
Forex kalkulačky
Forex Tepelná mapa
Indicators Heatmap
Komunita
Komunita
Systémy
Najpopulárnejšie systémy
Stratégie
Súťaže
Forexové grafy
Forexový sentiment
Indikátor Outlook
Recenzie
Brokeri
Prop Trading Firms
Služby VPS
Poskytovatelia signálu
Služby programovania EA
Affiliate Programs
Služby brokera PAMM
Služby zľavového programu
Obchodné platformy
Odborní poradcovia
Kryptoburzy
Trading Courses
Brokeri
Forex Spready
Ponuky Forex brokerov
Swapy Forex brokerov
Objem brokera Forexu
Propagačné akcie Forex Brokera Broker News
Platforma
Miniaplikácie
Funkcie
API
RSS
Stock Portfolio
Affiliate Software
Rozšírené grafy
Podpora
FAQ
Pomoc
Kontaktuj nás
Nahlásiť chybu!
O
Blog
& copy; 2024 Myfxbook Ltd. Všetky práva vyhradené.
UPOZORNENIE NA VYSOKÉ RIZIKO: Obchodovanie s devízami prináša vysokú úroveň rizika, ktoré nemusí byť vhodné pre všetkých investorov. Páka vytvára ďalšie riziká a straty. Než sa rozhodnete obchodovať s devízami, dôkladne zvážte svoje investičné ciele, úroveň skúseností a toleranciu voči riziku. Môžete prísť o časť alebo všetky svoje počiatočné investície. Neinvestujte peniaze, ktoré si nemôžete dovoliť stratiť. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Všetky údaje a informácie sú poskytované „tak, ako sú“. iba na informačné účely a nie je určené na obchodné účely alebo rady. Výkonnosť v minulosti neznamená výkonnosť v budúcnosti.